DIANT Pharma's founder and CEO Antonio Costa, Ph.D., discusses how the advent of mRNA-based therapeutics and vaccines has increased the demand for lipid nanoparticles (LNPs), and how critical advanced manufacturing processes will be in ensuring the quality and scalability as their use continues to grow.
.svg)
